STOCK TITAN

Cytek Biosciences (CTKB) holders report over 7% stakes in Schedule 13G/A

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Cytek Biosciences, Inc. received an amended Schedule 13G/A disclosing significant ownership positions by Millennium-affiliated entities and Israel A. Englander. Integrated Core Strategies (US) LLC reports beneficial ownership of 7,162,923 shares of common stock, representing 5.5% of the class, all with shared voting and dispositive power. Millennium Management LLC, Millennium Group Management LLC, and Mr. Englander each report beneficial ownership of 9,338,010 shares, or 7.2% of the class, also solely through shared voting and dispositive power. The filing explains that the securities are held by entities subject to voting control and investment discretion of Millennium Management LLC and related managers, and it includes language that this structure should not, by itself, be construed as an admission of beneficial ownership by these reporting persons.

Positive

  • None.

Negative

  • None.
Integrated Core Strategies shares 7,162,923 shares Beneficially owned Cytek Biosciences common stock; Item 9 cover page
Integrated Core Strategies ownership 5.5 % Percent of Cytek Biosciences common stock class; Item 11 cover page
Millennium entities shares 9,338,010 shares Beneficially owned Cytek Biosciences common stock; Item 9 cover pages
Millennium entities ownership 7.2 % Percent of Cytek Biosciences common stock class; Item 11 cover pages
CUSIP 23285D109 Cytek Biosciences common stock identifier listed in Item 1 and Item 2
Certification date 08/05/2026 Signature dates of reporting persons on the Schedule 13G/A amendment
Schedule 13G/A regulatory
"received an amended Schedule 13G/A disclosing significant ownership positions"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
beneficially owned financial
"Amount beneficially owned: See response to Item 9 on each cover page"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power financial
"Shared Voting Power 7,162,923.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 9,338,010.00"
investment discretion financial
"subject to voting control and investment discretion by Millennium Management LLC"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What ownership stake in Cytek Biosciences (CTKB) does Integrated Core Strategies (US) LLC report?

Integrated Core Strategies (US) LLC reports beneficial ownership of 7,162,923 shares of Cytek Biosciences common stock, representing 5.5% of the outstanding class. All of these shares are reported with shared voting and shared dispositive power, and none with sole authority.

How many Cytek Biosciences (CTKB) shares do Millennium entities and Israel A. Englander report owning?

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report 9,338,010 shares of Cytek Biosciences common stock, equal to 7.2% of the class. These holdings are reported entirely as shares over which they have shared voting and shared dispositive power.

Do the Millennium reporting persons have sole voting power over Cytek Biosciences (CTKB) shares?

The reporting persons disclose 0 shares with sole voting power and only shared voting power over their Cytek Biosciences holdings. They similarly report 0 shares with sole dispositive power and list their entire reported positions under shared dispositive power instead.

What does this Schedule 13G/A amendment indicate about control over CTKB shares?

The amendment states the securities are held by entities subject to voting control and investment discretion of Millennium Management LLC and related managers. It also notes this structure should not be construed, by itself, as an admission of beneficial ownership by the Millennium reporting persons.

Who are the reporting persons on this Cytek Biosciences (CTKB) Schedule 13G/A amendment?

The reporting persons are Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. All list the Cytek Biosciences common stock (CUSIP 23285D109) as the relevant security class.





23285D109

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Integrated Core Strategies (US) LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:08/05/2026
Millennium Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:08/05/2026
Millennium Group Management LLC
Signature:/s/ Gil Raviv
Name/Title:Gil Raviv, Global General Counsel
Date:08/05/2026
Israel A. Englander
Signature:/s/ Israel A. Englander
Name/Title:Israel A. Englander
Date:08/05/2026

Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner
Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of August 5, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.